V
Verve Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2018 · IPO 2021 Unicorn
Focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary
Global footprint
Where Verve Therapeutics has talent and traffic
(2 of 161 staff)
team presence
across markets
Patent intelligence
$22M patent portfolio · 12 active families
Where Verve Therapeutics concentrates vs peers
Each axis is a top-10 topic across Verve Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Sentiment on X
What X is saying about Verve Therapeutics
An AI-synthesized read of the highest-engagement posts about Verve Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Verve Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.